Summit Therapeutics shares tumble 20% after interim Phase 3 miss for ivonescimab
read at Endpoints ↗Negative readoutNegative
Summit Therapeutics saw its shares fall about 20% after the market close on Thursday.
The decline came after an interim analysis of a Phase 3 trial for its cancer candidate ivonescimab failed to meet a predefined statistical endpoint in a subset of patients.
Investors interpreted the miss as a setback for the drug’s development timeline, heightening frustration among shareholders.
The company has not released further details, and the sharp price move reflects the market’s sensitivity to trial data signals.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Summit slips on ivonescimab's apparent interim miss in sign of investor frustration”
read at Endpoints ↗83 words · retrieved May 1
comments(0)
5-min edit window · permanent after that